Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients.
Clé DV, Hirayama AV, Alencar AJ, Costa LJ, Feliciano JVP, Mattos ER, Cordeiro AC, Salvino MA, Barros GMN, de Lima M, Scheinberg P, Guerino-Cunha RL. Clé DV, et al. Among authors: hirayama av. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S3-S12. doi: 10.1016/j.htct.2021.09.001. Hematol Transfus Cell Ther. 2021. PMID: 34794793 Free PMC article.
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Cordeiro A, et al. Among authors: hirayama av. Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13. Biol Blood Marrow Transplant. 2020. PMID: 31419568 Free PMC article. Clinical Trial.
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
Seber A, de CastroJunior CG, Kerbauy LN, Hirayama AV, Bonfim C, Fernandes JF, Souza M, Schafell R, Nabhan S, Loggetto SR, Simões BP, Rocha V, de Lima M, Guerino-Cunha RL, Bittencourt H. Seber A, et al. Among authors: hirayama av. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S13-S21. doi: 10.1016/j.htct.2021.09.002. Hematol Transfus Cell Ther. 2021. PMID: 34794791 Free PMC article.
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
Alencar AJ, Hirayama AV, Clé DV, Salvino MA, Perini G, Arrais C, Baiocchi O, Palma LC, Colturato I, Vaz J, Chiattone R, de Lima M, Filho JS, Nabhan S, Rocha V, Guerino-Cunha RL, Chiattone CS. Alencar AJ, et al. Among authors: hirayama av. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S22-S29. doi: 10.1016/j.htct.2021.09.003. Hematol Transfus Cell Ther. 2021. PMID: 34794792 Free PMC article.
Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV, Turtle CJ. Hirayama AV, et al. Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. Am J Hematol. 2019. PMID: 30784102 Free article. Review.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: hirayama av. Blood. 2021 Jan 21;137(3):323-335. doi: 10.1182/blood.2020006770. Blood. 2021. PMID: 32967009 Free PMC article. Clinical Trial.
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ. Hay KA, et al. Among authors: hirayama av. Blood. 2019 Apr 11;133(15):1652-1663. doi: 10.1182/blood-2018-11-883710. Epub 2019 Feb 6. Blood. 2019. PMID: 30728140 Free PMC article. Clinical Trial.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A, Perkins P, Kirk A, Shadman M, Chow VA, Gopal AK, Hodges Dwinal A, Williamson S, Myers J, Chen A, Nagle S, Hayes-Lattin B, Schachter L, Maloney DG, Turtle CJ, Sorror ML, Maziarz RT. Gauthier J, et al. Among authors: hirayama av. Blood. 2022 Jun 30;139(26):3722-3731. doi: 10.1182/blood.2021014497. Blood. 2022. PMID: 35439295 Free PMC article.
32 results